The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Rational design of shepherdin, a novel anticancer agent
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Cytoprotective membrane-permeable peptides designed from the Bax-binding domain of Ku70
Sawada, M., Hayes, P., & Matsuyama, S. (2003) · Nature Cell Biology · doi:10.1038/ncb955 · Cited by 161
RetractedEGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 2×
“…which indistinguishably affected tumor cell types of different derivations, regardless of their proliferative condition (Swanton, 2004), p53 status (Vogelstein et al., 2000), or overexpression of potent survival signals, e.g., Bcl-2 (Johnstone et al., 2002), all conditions that typically…”
BackgroundIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Johnstone (2002) · doi:10.1016/s0092-8674(02)00625-6 · Cited by 1,876
Control of apoptosis and mitotic spindle checkpoint by survivin
Li, F., Ambrosini, G., Chu, E. Y., Plescia, J., Tognin, S., Marchisio, P. C., & Altieri, D. C. (1998) · Nature · doi:10.1038/25141 · Cited by 1,870
Self-citationA high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C., & Burrows, F. J. (2003) · Nature · doi:10.1038/nature01913 · Cited by 1,387
Stebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., & Pavletich, N. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80203-2 · Cited by 1,364
Validating survivin as a cancer therapeutic target
Altieri, D. C. (2003) · Nature Reviews Cancer · doi:10.1038/nrc968 · Cited by 1,206
Self-citation
Cited by
Targeting mitochondria for cancer therapy
Fulda, S., Galluzzi, L., & Kroemer, G. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3137 · Cited by 1,629
Survivin, cancer networks and pathway-directed drug discovery
Altieri, D. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2293 · Cited by 994
Self-citationApoptosis and cancer: mutations within caspase genes
Ghavami, S., Hashemi, M., Ande, S. R., Yeganeh, B., Xiao, W., Eshraghi, M., Bus, C. J., Kadkhoda, K., Wiechec, E., Halayko, A. J., et al. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2009.066944 · Cited by 713
IAP-targeted therapies for cancer
LaCasse, E. C., Mahoney, D. J., Cheung, H. H., Plenchette, S., Baird, S., & Korneluk, R. G. (2008) · Oncogene · doi:10.1038/onc.2008.302 · Cited by 524
Survivin, a cancer target with an emerging role in normal adult tissues
Fukuda, S., & Pelus, L. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0375 · Cited by 465
Targeting heat shock proteins in cancer
Jego, G., Hazoumé, A., Seigneuric, R., & Garrido, C. (2013) · Cancer Letters · doi:10.1016/j.canlet.2010.10.014 · Cited by 452
Erkizan, H. V., Kong, Y., Merchant, M., Schlottmann, S., Barber-Rotenberg, J. S., Yuan, L., Abaan, O. D., Chou, T.-H., Dakshanamurthy, S., Brown, M. L., et al. (2009) · Nature Medicine · doi:10.1038/nm.1983 · Cited by 452
The Hsp90 molecular chaperone: an open and shut case for treatment
Pearl, L. H., Prodromou, C., & Workman, P. (2008) · Biochemical Journal · doi:10.1042/bj20071640 · Cited by 447
Regulation of Tumor Cell Mitochondrial Homeostasis by an Organelle-Specific Hsp90 Chaperone Network
Kang, B. H., Plescia, J., Dohi, T., Rosa, J., Doxsey, S. J., & Altieri, D. C. (2007) · Cell · doi:10.1016/j.cell.2007.08.028 · Cited by 443
Self-citationCell-penetrating peptides as delivery vehicles for biology and medicine
Stewart, K. M., Horton, K. L., & Kelley, S. O. (2008) · Organic & Biomolecular Chemistry · doi:10.1039/b719950c · Cited by 381
Survivin: A new target for anti-cancer therapy
Ryan, B. M., O’Donovan, N., & Duffy, M. J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.05.003 · Cited by 379
Heat shock protein 90: The cancer chaperone
Neckers, L. (2007) · Journal of Biosciences · doi:10.1007/s12038-007-0051-y · Cited by 365
Jackson, S. E. (2012) · Topics in Current Chemistry · doi:10.1007/128_2012_356 · Cited by 338
Wheatley, S. P., & Altieri, D. C. (2019) · Journal of Cell Science · doi:10.1242/jcs.223826 · Cited by 337
Self-citationInhibition of CDK1 as a potential therapy for tumors over-expressing MYC
Goga, A., Yang, D., Tward, A. D., Morgan, D. O., & Bishop, J. M. (2007) · Nature Medicine · doi:10.1038/nm1606 · Cited by 326
Inhibitors of the heat shock response: Biology and pharmacology
Powers, M. V., & Workman, P. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.05.040 · Cited by 320
Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery
MAE, M., & LANGEL, U. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.04.004 · Cited by 317
Withaferin A targets heat shock protein 90 in pancreatic cancer cells
Yu, Y., Hamza, A., Zhang, T., Gu, M., Zou, P., Newman, B., Li, Y., Gunatilaka, A. A. L., Zhan, C.-G., & Sun, D. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.09.017 · Cited by 316
Hsp60 Regulation of Tumor Cell Apoptosis
Ghosh, J. C., Dohi, T., Kang, B. H., & Altieri, D. C. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m705904200 · Cited by 310
Self-citationInhibitors of the HSP90 Molecular Chaperone: Current Status
(2006) · Advances in Cancer Research · doi:10.1016/s0065-230x(06)95009-x · Cited by 310
Current status and perspectives of patient-derived xenograft models in cancer research
Lai, Y., Wei, X., Lin, S., Qin, L., Cheng, L., & Li, P. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0470-7 · Cited by 295
Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update
Ciocca, D. R., Arrigo, A. P., & Calderwood, S. K. (2013) · Archives of Toxicology · doi:10.1007/s00204-012-0918-z · Cited by 265
Survivin is released from cancer cells via exosomes
Khan, S., Jutzy, J. M. S., Aspe, J. R., McGregor, D. W., Neidigh, J. W., & Wall, N. R. (2011) · Apoptosis · doi:10.1007/s10495-010-0534-4 · Cited by 265
Hong, D. S., Banerji, U., Tavana, B., George, G. C., Aaron, J., & Kurzrock, R. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.10.001 · Cited by 259
Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer
Bolhassani, A. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.07.006 · Cited by 257
Old and New Approaches to Target the Hsp90 Chaperone
Sanchez, J., Carter, T. R., Cohen, M. S., & Blagg, B. S. J. (2020) · Current Cancer Drug Targets · doi:10.2174/1568009619666191202101330 · Cited by 183
Aspe, J. R., Diaz Osterman, C. J., Jutzy, J. M. S., Deshields, S., Whang, S., & Wall, N. R. (2014) · Journal of Extracellular Vesicles · doi:10.3402/jev.v3.23244 · Cited by 126
Hsp90 inhibitors as senolytic drugs to extend healthy aging
Fuhrmann-Stroissnigg, H., Niedernhofer, L. J., & Robbins, P. D. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1475828 · Cited by 92
TRAP1 in Oxidative Stress and Neurodegeneration
Ramos Rego, I., Santos Cruz, B., Ambrósio, A. F., & Alves, C. H. (2021) · Antioxidants · doi:10.3390/antiox10111829 · Cited by 44
Metadata
- Authors
- Plescia, J., Salz, W., Xia, F., Pennati, M., Zaffaroni, N., Daidone, M. G., Meli, M., Dohi, T., Fortugno, P., Nefedova, Y., Gabrilovich, D. I., Colombo, G., & Altieri, D. C.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2005-05
- Volume
- 7
- Issue
- 5
- Pages
- 457-468
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2096088010
- Cited by
- 341
- References
- 40
- FWCI
- 7.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.